Pathway Expands Medical AI Platform with Drug Reference and Interaction Checker

Business Wire

14-05-2025

MONTREAL--(BUSINESS WIRE)-- Pathway today announced the launch of a fully integrated drug reference and drug-drug interaction checker within its AI-powered medical knowledge platform. Clinicians can now access comprehensive medication information for over 2,000 drugs and screen for interactions directly within the same interface they already use for clinical guidance.
Built on Pathway's proprietary AI-first drug database, clinicians can now check interactions and access trusted dosing guidance in seconds within the Pathway platform.
Share
Pathway's drug reference is powered by a proprietary database that is uniquely structured to support AI-native use. It enables consistent, context-aware access to medication data across thousands of clinical scenarios. This foundation is further complemented by trusted sources like the American Hospital Formulary Service (AHFS), a gold-standard reference maintained by the American Society of Health-System Pharmacists (ASHP) and widely used by clinicians and institutions across the United States. Together, this combined data supports clinically relevant and responsible integration within the Pathway platform.
'Clinicians face constant time pressure and information overload,' said Dr. Louis Mullie, Chief Medical Officer at Pathway. 'We built this to keep prescribing information within the flow of care. Medication errors affect over a million patients annually in the U.S., often due to incomplete information or workflow disruptions. By enabling instant access to full monographs and interaction guidance within the Pathway AI experience, we help clinicians make safer and faster decisions without disrupting their workflow.'
Clinicians can now ask drug-related questions in plain language through Pathway AI, such as 'What is the dose of pregabalin for postherpetic neuralgia?' or 'What is the dose of bupropion for depression in a patient with liver cirrhosis?', and receive clear, structured answers in seconds. Pathway's new interaction checker also enables quick screening for potential conflicts between medications without needing to switch tools or interrupt patient care.
'At Mee Memorial, Pathway has become an essential part of how we deliver care,' said Dr. Noah Hawthorne, MPH, Chief Medical Officer at Mee Memorial Healthcare System. 'More than half of our searches involve drug information. Pathway's integrated medication database consistently delivers reliable, fast answers, whether for routine prescriptions or complex, patient-specific decisions.'
This achievement highlights Pathway's continued leadership at the intersection of AI and clinical decision support. In 2024, the platform became the first generative AI tool in medicine to offer continuing medical education (CME) credit for every question asked, embedding ongoing education into everyday use. In March 2025, the company also introduced HIPAA-compliant access for Pathway Plus subscribers, supporting secure and compliant use of patient-specific information in AI queries. Earlier this month, Pathway's proprietary 'Deep' model achieved the highest score ever reported for any publicly available specialized medical AI.
About Pathway
Pathway is one of the most widely used AI-powered medical platforms, designed to support real-time clinical decision-making. It helps clinicians work more efficiently, reduce burnout, and stay current with evidence-based guidelines and literature. Combining advanced AI with proprietary data and structured medical knowledge, Pathway delivers fast, transparent answers to complex clinical questions. The platform is built for accuracy, safety, and ease of use, and is used by clinicians in over 10,000 care centers across the United States and internationally.
To learn more or try Pathway, visit www.pathway.md